Caribou announced that the FDA has granted Regenerative Medicine Advanced Therapy designation to CB-011 for relapsed or refractory multiple myeloma. CB-011, an allogeneic anti-BCMA CAR-T cell therapy, is being evaluated in the company’s ongoing open-label, multicenter CaMMouflage phase 1 clinical trial evaluating patients with r/r MM.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRBU:
- Caribou Biosciences price target raised to $13 from $11 at Evercore ISI
- Caribou Biosciences: Advancing Allogeneic Cell Therapy Pipeline and Pivotal Trial Plans Support High-Risk Buy Rating
- Drug Pricing Reforms Threaten Caribou Biosciences’ Future Margins and Market Access
- Caribou Biosciences reports Q4 EPS (28c) vs. (39c) last year
- Here is a List of Small-Cap Biotech ETFs to Watch for Big Gains in 2026